TY - JOUR
T1 - Expression, clinical significance, and receptor identification of the newest B7 family member HHLA2 protein
AU - Janakiram, Murali
AU - Chinai, Jordan M.
AU - Fineberg, Susan
AU - Fiser, Andras
AU - Montagna, Cristina
AU - Medavarapu, Ramadevi
AU - Castano, Ekaterina
AU - Jeon, Hyungjun
AU - Ohaegbulam, Kim C.
AU - Zhao, Ruihua
AU - Zhao, Aimin
AU - Almo, Steven C.
AU - Sparano, Joseph A.
AU - Zang, Xingxing
N1 - Publisher Copyright:
© 2015 American Association for Cancer Research.
PY - 2015/5/15
Y1 - 2015/5/15
N2 - Purpose: HHLA2 (B7H7/B7-H5/B7y) is a newly identified B7 familymember that regulates human T-cell functions. However, its protein expression in human organs and significance in human diseases are unknown. The objective of this study was to analyze HHLA2protein expression innormalhuman tissues and cancers, as well as its prognostic significance, to explore mechanisms regulatingHHLA2 expression, and to identify candidateHHLA2 receptors. Experimental Design: An immunohistochemistry protocol and a flow cytometry assay with newly generated monoclonal antibodies were developed to examine HHLA2 protein. HHLA2 gene copy-number variation was analyzed from cancer genomic data. The combination of bioinformatics analysis and immunologic approaches was established to explore HHLA2 receptors. Results: HHLA2 protein was detected in trophoblastic cells of the placenta and the epithelium of gut, kidney, gallbladder, and breast, but not in most other organs. In contrast, HHLA2 protein was widely expressed in human cancers from the breast, lung, thyroid, melanoma, pancreas, ovary, liver, bladder, colon, prostate, kidney, and esophagus. In a cohort of 50 patients with stage I-III triple-negative breast cancer, 56% of patients had aberrant expression of HHLA2 on their tumors, and high HHLA2 expression was significantly associated with regional lymph node metastasis and stage. The Cancer Genome Atlas revealed that HHLA2 copy-number gains were present in 29% of basal breast cancers, providing a potential mechanism for increased HHLA2 protein expression in breast cancer. Finally, Transmembrane and Immunoglobulin Domain Containing 2 (TMIGD2) was identified as one of the receptors for HHLA2. Conclusions: Wide expression of HHLA2 in human malignancies, together with its association with poor prognostic factors and its T-cell coinhibitory capability, suggests that the HHLA2 pathway represents a novel immunosuppressive mechanism within the tumor microenvironment and an attractive target for human cancer therapy.
AB - Purpose: HHLA2 (B7H7/B7-H5/B7y) is a newly identified B7 familymember that regulates human T-cell functions. However, its protein expression in human organs and significance in human diseases are unknown. The objective of this study was to analyze HHLA2protein expression innormalhuman tissues and cancers, as well as its prognostic significance, to explore mechanisms regulatingHHLA2 expression, and to identify candidateHHLA2 receptors. Experimental Design: An immunohistochemistry protocol and a flow cytometry assay with newly generated monoclonal antibodies were developed to examine HHLA2 protein. HHLA2 gene copy-number variation was analyzed from cancer genomic data. The combination of bioinformatics analysis and immunologic approaches was established to explore HHLA2 receptors. Results: HHLA2 protein was detected in trophoblastic cells of the placenta and the epithelium of gut, kidney, gallbladder, and breast, but not in most other organs. In contrast, HHLA2 protein was widely expressed in human cancers from the breast, lung, thyroid, melanoma, pancreas, ovary, liver, bladder, colon, prostate, kidney, and esophagus. In a cohort of 50 patients with stage I-III triple-negative breast cancer, 56% of patients had aberrant expression of HHLA2 on their tumors, and high HHLA2 expression was significantly associated with regional lymph node metastasis and stage. The Cancer Genome Atlas revealed that HHLA2 copy-number gains were present in 29% of basal breast cancers, providing a potential mechanism for increased HHLA2 protein expression in breast cancer. Finally, Transmembrane and Immunoglobulin Domain Containing 2 (TMIGD2) was identified as one of the receptors for HHLA2. Conclusions: Wide expression of HHLA2 in human malignancies, together with its association with poor prognostic factors and its T-cell coinhibitory capability, suggests that the HHLA2 pathway represents a novel immunosuppressive mechanism within the tumor microenvironment and an attractive target for human cancer therapy.
UR - http://www.scopus.com/inward/record.url?scp=84938317531&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84938317531&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-14-1495
DO - 10.1158/1078-0432.CCR-14-1495
M3 - Article
C2 - 25549724
AN - SCOPUS:84938317531
SN - 1078-0432
VL - 21
SP - 2359
EP - 2366
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 10
ER -